Zur Kurzanzeige

2020-05-11Zeitschriftenartikel DOI: 10.1186/s13601-020-00317-y
EAACI Task force Clinical epidemiology of anaphylaxis: experts' perspective on the use of adrenaline autoinjectors in Europe
dc.contributor.authorKraft, Magdalena
dc.contributor.authorDölle-Bierke, Sabine
dc.contributor.authorTurner, Paul J.
dc.contributor.authorFernández-Rivas, Montserrat
dc.contributor.authorGrabenhenrich, Linus
dc.contributor.authorWorm, Margitta
dc.date.accessioned2026-09-25T15:56:01Z
dc.date.available2026-09-25T15:56:01Z
dc.date.issued2020-05-11none
dc.identifier.urihttp://edoc.rki.de/176904/13953
dc.description.abstractBackground Worldwide, guidelines recommend the use of adrenaline autoinjectors (AAIs) for self-medication in patients who experience severe allergic reaction. The European Medical Agency recommends the prescription of two AAIs, which should be carried by patients at all times. The European Academy of Allergy and Clinical Immunology guidelines propose to prescribe a second AAI under some defined conditions. In the present study, we aimed to examine the adherence to these guidelines and prescription behavior of allergy experts regarding the number of AAIs prescribed for a given patient. Methods A standardized questionnaire was applied to the participants of the 5th International Conference of the Network of Online Registration for Anaphylaxis (NORA e. V.). Twenty-six experts (medical doctors with at least 2 years of experience in the field of anaphylaxis) answered the questions regarding the number of autoinjectors prescribed and the reasons influencing their decisions. Results Sixty-eight percent of the experts usually prescribed one AAI, while 32% prescribed two. The pediatricians and physicians with less experience tended to prescribe two autoinjectors more frequently. The experts were more likely to prescribe two adrenaline autoinjectors if the patient was a child, had a previous severe reaction, had mastocytosis, asthma, cardiovascular disease, or high body weight, or lived far from the emergency department. Conclusion Our data confirm the lack of consensus regarding the number of AAIs to prescribe. Despite the European Medical Agency recommendation, the majority of allergy experts prescribed one autoinjector per patient. However, under distinct circumstances (e.g. mastocytosis, asthma, excess body weight, a history of severe anaphylaxis, or restricted access to immediate emergency), experts tended to prescribe more AAIs, which is in accordance with the European Academy of Allergy and Clinical Immunology guidelines.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectAnaphlaxiseng
dc.subjectAnaphylactic reactioneng
dc.subjectAdrenaline autoinjectoreng
dc.subjectAAIeng
dc.subjectEpinephrine autoinjectoreng
dc.subjectEuropean Academy of Allergy and Clinical Immunology guidelineseng
dc.subjectEuropean Medical Agencyeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleEAACI Task force Clinical epidemiology of anaphylaxis: experts' perspective on the use of adrenaline autoinjectors in Europenone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/13953-6
dc.identifier.doi10.1186/s13601-020-00317-y
dc.type.versionpublishedVersionnone
local.edoc.container-titleClinical and Translational Allergynone
local.edoc.container-issn2045-7022none
local.edoc.pages5none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://link.springer.com/journal/13601none
local.edoc.container-publisher-nameSpringer Naturenone
local.edoc.container-volume10none
local.edoc.container-reportyear2020none
dc.description.versionPeer Reviewednone

Zur Kurzanzeige